Enveric Biosciences (ENVB) announced the issuance of a new U.S. patent covering a structurally diverse class of novel molecules with potential therapeutic applications for sleep and central nervous system disorders. The patent, titled, “Hydroxylated Psilocybin Derivatives and Methods of Using,” includes compounds demonstrating selective binding to the melatonin MT1 receptor. The company believes this new patent enhances its drug discovery platform and supports its CNS-focused strategy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Enveric Biosciences announces results from EB-003 trial
- Psychedelic: atai Life Sciences reports Phase 2a study data on BPL-003
- Enveric Biosciences files new provisional patent application
- VA secretary wants to find answers on psychedelics therapies, Politico says
- Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results